Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem Sells 11,250 Shares

Edwards Lifesciences Co. (NYSE:EW) CFO Scott B. Ullem sold 11,250 shares of the company’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total transaction of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Edwards Lifesciences Stock Performance

EW stock opened at $75.96 on Friday. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a twelve month low of $58.93 and a twelve month high of $96.12. The business’s fifty day moving average is $72.51 and its 200-day moving average is $69.36. The company has a market cap of $44.80 billion, a P/E ratio of 10.96, a price-to-earnings-growth ratio of 3.64 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Crowley Wealth Management Inc. acquired a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Millstone Evans Group LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $30,000. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $30,000. Finally, Prospera Private Wealth LLC bought a new position in Edwards Lifesciences during the third quarter worth about $32,000. Institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. The Goldman Sachs Group upped their price objective on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Piper Sandler raised their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the company a “neutral” rating in a report on Wednesday. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $82.00 to $90.00 in a research report on Monday, December 16th. Canaccord Genuity Group increased their target price on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday. Finally, Morgan Stanley lifted their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.